The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Subscribe To Our Newsletter & Stay Updated
